Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Brambatti, M., Darius, H., Oldgren, J., Clemens, A., Noack, H. H., Brueckmann, M., Yusuf, S., Wallentin, L., Ezekowitz, M. D., Connolly, S. J., & Healey, J. S. International Journal of Cardiology, 196:127–131, October, 2015.

Paper doi abstract bibtex

Objective: Diabetes mellitus (DM) is frequent among patients with atrial ﬁbrillation (AF). The RE-LY trial permits evaluation of patient characteristics, outcomes and the effectiveness of dabigatran etexilate among diabetic individuals. Methods: Patient characteristics and outcomes were compared between diabetic and non-diabetic patients and the relative efﬁcacy of each dose of dabigatran (150 mg bid and 110 mg bid) versus warfarin was evaluated. Results: Of 18,113 patients in RE-LY, 4221 patients (23.3%) had DM. Patients with DM were younger (70.9 vs. 71.7 years), more likely to have hypertension (86.6% vs. 76.5%), coronary artery disease (37.4% vs. 24.9%) and peripheral vascular disease (5.6% vs. 3.2%); (all p b 0.01). Time in therapeutic range for warfarin-treated patients was 65% for diabetic versus 68% for non-diabetic patients (p b 0.001). Regardless of assigned treatment, stroke or systemic embolism was more common among patients with DM (1.9% per year vs. 1.3% per year, p b 0.001). DM was also associated with an increased risk of death (5.1% per year vs. 3.5% per year, p b 0.001) and major bleeding (4.2% per year vs. 3.0% per year, p b 0.001). The absolute reduction in stroke or systemic embolism with dabigatran compared to warfarin was greater among patients with DM than those without DM (dabigatran 110 mg: 0.59% per year vs. 0.05% per year; dabigatran 150 mg: 0.89% per year vs. 0.51% per year). Conclusions: Compared to non-DM patients, AF patients with DM derive a greater absolute risk reduction in embolic events when treated with dabigatran. ClinicalTrials.gov Identiﬁer: NCT00262600. © 2015 Elsevier Ireland Ltd. All rights reserved.

@article{brambatti_comparison_2015-1,
	title = {Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: {Results} from the {RE}-{LY} trial},
	volume = {196},
	issn = {01675273},
	shorttitle = {Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S0167527315012255},
	doi = {10.1016/j.ijcard.2015.05.141},
	abstract = {Objective: Diabetes mellitus (DM) is frequent among patients with atrial ﬁbrillation (AF). The RE-LY trial permits evaluation of patient characteristics, outcomes and the effectiveness of dabigatran etexilate among diabetic individuals. Methods: Patient characteristics and outcomes were compared between diabetic and non-diabetic patients and the relative efﬁcacy of each dose of dabigatran (150 mg bid and 110 mg bid) versus warfarin was evaluated. Results: Of 18,113 patients in RE-LY, 4221 patients (23.3\%) had DM. Patients with DM were younger (70.9 vs. 71.7 years), more likely to have hypertension (86.6\% vs. 76.5\%), coronary artery disease (37.4\% vs. 24.9\%) and peripheral vascular disease (5.6\% vs. 3.2\%); (all p b 0.01). Time in therapeutic range for warfarin-treated patients was 65\% for diabetic versus 68\% for non-diabetic patients (p b 0.001). Regardless of assigned treatment, stroke or systemic embolism was more common among patients with DM (1.9\% per year vs. 1.3\% per year, p b 0.001). DM was also associated with an increased risk of death (5.1\% per year vs. 3.5\% per year, p b 0.001) and major bleeding (4.2\% per year vs. 3.0\% per year, p b 0.001). The absolute reduction in stroke or systemic embolism with dabigatran compared to warfarin was greater among patients with DM than those without DM (dabigatran 110 mg: 0.59\% per year vs. 0.05\% per year; dabigatran 150 mg: 0.89\% per year vs. 0.51\% per year). Conclusions: Compared to non-DM patients, AF patients with DM derive a greater absolute risk reduction in embolic events when treated with dabigatran. ClinicalTrials.gov Identiﬁer: NCT00262600. © 2015 Elsevier Ireland Ltd. All rights reserved.},
	language = {en},
	urldate = {2019-05-01},
	journal = {International Journal of Cardiology},
	author = {Brambatti, Michela and Darius, Harald and Oldgren, Jonas and Clemens, Andreas and Noack, Herbert H. and Brueckmann, Martina and Yusuf, Salim and Wallentin, Lars and Ezekowitz, Michael D. and Connolly, Stuart J. and Healey, Jeff S.},
	month = oct,
	year = {2015},
	pages = {127--131},
	file = {Brambatti et al. - 2015 - Comparison of dabigatran versus warfarin in diabet.pdf:/Users/neil.hawkins/Zotero/storage/7LZM939B/Brambatti et al. - 2015 - Comparison of dabigatran versus warfarin in diabet.pdf:application/pdf},
}

Downloads: 0

{"_id":"LcEoato5xLXoAr8Nz","bibbaseid":"brambatti-darius-oldgren-clemens-noack-brueckmann-yusuf-wallentin-etal-comparisonofdabigatranversuswarfarinindiabeticpatientswithatrialfibrillationresultsfromtherelytrial-2015","author_short":["Brambatti, M.","Darius, H.","Oldgren, J.","Clemens, A.","Noack, H. H.","Brueckmann, M.","Yusuf, S.","Wallentin, L.","Ezekowitz, M. D.","Connolly, S. J.","Healey, J. S."],"bibdata":{"bibtype":"article","type":"article","title":"Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial","volume":"196","issn":"01675273","shorttitle":"Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation","url":"https://linkinghub.elsevier.com/retrieve/pii/S0167527315012255","doi":"10.1016/j.ijcard.2015.05.141","abstract":"Objective: Diabetes mellitus (DM) is frequent among patients with atrial ﬁbrillation (AF). The RE-LY trial permits evaluation of patient characteristics, outcomes and the effectiveness of dabigatran etexilate among diabetic individuals. Methods: Patient characteristics and outcomes were compared between diabetic and non-diabetic patients and the relative efﬁcacy of each dose of dabigatran (150 mg bid and 110 mg bid) versus warfarin was evaluated. Results: Of 18,113 patients in RE-LY, 4221 patients (23.3%) had DM. Patients with DM were younger (70.9 vs. 71.7 years), more likely to have hypertension (86.6% vs. 76.5%), coronary artery disease (37.4% vs. 24.9%) and peripheral vascular disease (5.6% vs. 3.2%); (all p b 0.01). Time in therapeutic range for warfarin-treated patients was 65% for diabetic versus 68% for non-diabetic patients (p b 0.001). Regardless of assigned treatment, stroke or systemic embolism was more common among patients with DM (1.9% per year vs. 1.3% per year, p b 0.001). DM was also associated with an increased risk of death (5.1% per year vs. 3.5% per year, p b 0.001) and major bleeding (4.2% per year vs. 3.0% per year, p b 0.001). The absolute reduction in stroke or systemic embolism with dabigatran compared to warfarin was greater among patients with DM than those without DM (dabigatran 110 mg: 0.59% per year vs. 0.05% per year; dabigatran 150 mg: 0.89% per year vs. 0.51% per year). Conclusions: Compared to non-DM patients, AF patients with DM derive a greater absolute risk reduction in embolic events when treated with dabigatran. ClinicalTrials.gov Identiﬁer: NCT00262600. © 2015 Elsevier Ireland Ltd. All rights reserved.","language":"en","urldate":"2019-05-01","journal":"International Journal of Cardiology","author":[{"propositions":[],"lastnames":["Brambatti"],"firstnames":["Michela"],"suffixes":[]},{"propositions":[],"lastnames":["Darius"],"firstnames":["Harald"],"suffixes":[]},{"propositions":[],"lastnames":["Oldgren"],"firstnames":["Jonas"],"suffixes":[]},{"propositions":[],"lastnames":["Clemens"],"firstnames":["Andreas"],"suffixes":[]},{"propositions":[],"lastnames":["Noack"],"firstnames":["Herbert","H."],"suffixes":[]},{"propositions":[],"lastnames":["Brueckmann"],"firstnames":["Martina"],"suffixes":[]},{"propositions":[],"lastnames":["Yusuf"],"firstnames":["Salim"],"suffixes":[]},{"propositions":[],"lastnames":["Wallentin"],"firstnames":["Lars"],"suffixes":[]},{"propositions":[],"lastnames":["Ezekowitz"],"firstnames":["Michael","D."],"suffixes":[]},{"propositions":[],"lastnames":["Connolly"],"firstnames":["Stuart","J."],"suffixes":[]},{"propositions":[],"lastnames":["Healey"],"firstnames":["Jeff","S."],"suffixes":[]}],"month":"October","year":"2015","pages":"127–131","file":"Brambatti et al. - 2015 - Comparison of dabigatran versus warfarin in diabet.pdf:/Users/neil.hawkins/Zotero/storage/7LZM939B/Brambatti et al. - 2015 - Comparison of dabigatran versus warfarin in diabet.pdf:application/pdf","bibtex":"@article{brambatti_comparison_2015-1,\n\ttitle = {Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: {Results} from the {RE}-{LY} trial},\n\tvolume = {196},\n\tissn = {01675273},\n\tshorttitle = {Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0167527315012255},\n\tdoi = {10.1016/j.ijcard.2015.05.141},\n\tabstract = {Objective: Diabetes mellitus (DM) is frequent among patients with atrial ﬁbrillation (AF). The RE-LY trial permits evaluation of patient characteristics, outcomes and the effectiveness of dabigatran etexilate among diabetic individuals. Methods: Patient characteristics and outcomes were compared between diabetic and non-diabetic patients and the relative efﬁcacy of each dose of dabigatran (150 mg bid and 110 mg bid) versus warfarin was evaluated. Results: Of 18,113 patients in RE-LY, 4221 patients (23.3\\%) had DM. Patients with DM were younger (70.9 vs. 71.7 years), more likely to have hypertension (86.6\\% vs. 76.5\\%), coronary artery disease (37.4\\% vs. 24.9\\%) and peripheral vascular disease (5.6\\% vs. 3.2\\%); (all p b 0.01). Time in therapeutic range for warfarin-treated patients was 65\\% for diabetic versus 68\\% for non-diabetic patients (p b 0.001). Regardless of assigned treatment, stroke or systemic embolism was more common among patients with DM (1.9\\% per year vs. 1.3\\% per year, p b 0.001). DM was also associated with an increased risk of death (5.1\\% per year vs. 3.5\\% per year, p b 0.001) and major bleeding (4.2\\% per year vs. 3.0\\% per year, p b 0.001). The absolute reduction in stroke or systemic embolism with dabigatran compared to warfarin was greater among patients with DM than those without DM (dabigatran 110 mg: 0.59\\% per year vs. 0.05\\% per year; dabigatran 150 mg: 0.89\\% per year vs. 0.51\\% per year). Conclusions: Compared to non-DM patients, AF patients with DM derive a greater absolute risk reduction in embolic events when treated with dabigatran. ClinicalTrials.gov Identiﬁer: NCT00262600. © 2015 Elsevier Ireland Ltd. All rights reserved.},\n\tlanguage = {en},\n\turldate = {2019-05-01},\n\tjournal = {International Journal of Cardiology},\n\tauthor = {Brambatti, Michela and Darius, Harald and Oldgren, Jonas and Clemens, Andreas and Noack, Herbert H. and Brueckmann, Martina and Yusuf, Salim and Wallentin, Lars and Ezekowitz, Michael D. and Connolly, Stuart J. and Healey, Jeff S.},\n\tmonth = oct,\n\tyear = {2015},\n\tpages = {127--131},\n\tfile = {Brambatti et al. - 2015 - Comparison of dabigatran versus warfarin in diabet.pdf:/Users/neil.hawkins/Zotero/storage/7LZM939B/Brambatti et al. - 2015 - Comparison of dabigatran versus warfarin in diabet.pdf:application/pdf},\n}\n\n","author_short":["Brambatti, M.","Darius, H.","Oldgren, J.","Clemens, A.","Noack, H. H.","Brueckmann, M.","Yusuf, S.","Wallentin, L.","Ezekowitz, M. D.","Connolly, S. J.","Healey, J. S."],"bibbaseid":"brambatti-darius-oldgren-clemens-noack-brueckmann-yusuf-wallentin-etal-comparisonofdabigatranversuswarfarinindiabeticpatientswithatrialfibrillationresultsfromtherelytrial-2015","role":"author","urls":{"Paper":"https://linkinghub.elsevier.com/retrieve/pii/S0167527315012255"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/myPubs.bib","dataSources":["ZaHtWavQhcwZqKLNF","iRRNaRs6FkffgErta","v8uQmZsBpiqycmskv"],"keywords":[],"search_terms":["comparison","dabigatran","versus","warfarin","diabetic","patients","atrial","fibrillation","results","trial","brambatti","darius","oldgren","clemens","noack","brueckmann","yusuf","wallentin","ezekowitz","connolly","healey"],"title":"Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial","year":2015}